These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24122221)

  • 21. Molecular Dynamics as a Tool for Virtual Ligand Screening.
    Menchon G; Maveyraud L; Czaplicki G
    Methods Mol Biol; 2018; 1762():145-178. PubMed ID: 29594772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Objective evaluation of analgesic effect of drugs in laboratory animals by a new methodological approach.
    Jezdinský J
    Acta Univ Palacki Olomuc Fac Med; 1982; 103():175-227. PubMed ID: 6242597
    [No Abstract]   [Full Text] [Related]  

  • 23. Integrating virtual screening in lead discovery.
    Oprea TI; Matter H
    Curr Opin Chem Biol; 2004 Aug; 8(4):349-58. PubMed ID: 15288243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virtual screening in lead discovery and optimization.
    Jain AN
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):396-403. PubMed ID: 15338948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virtual Discovery Europe--Select Biosciences Conference. Computer-aided drug design and screening.
    Kubinyi H
    IDrugs; 2007 Dec; 10(12):869-73. PubMed ID: 18041683
    [No Abstract]   [Full Text] [Related]  

  • 26. Discovery of non-peptide, small molecule antagonists of α9α10 nicotinic acetylcholine receptors as novel analgesics for the treatment of neuropathic and tonic inflammatory pain.
    Zheng G; Zhang Z; Dowell C; Wala E; Dwoskin LP; Holtman JR; McIntosh JM; Crooks PA
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2476-9. PubMed ID: 21397497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of computational methods in the identification of bioactive compounds.
    Glick M; Jacoby E
    Curr Opin Chem Biol; 2011 Aug; 15(4):540-6. PubMed ID: 21411361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.
    Jahangir A; Alam M; Carter DS; Dillon MP; Bois DJ; Ford AP; Gever JR; Lin C; Wagner PJ; Zhai Y; Zira J
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1632-5. PubMed ID: 19231178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The discovery and development of analgesics: new mechanisms, new modalities.
    Burgess G; Williams D
    J Clin Invest; 2010 Nov; 120(11):3753-9. PubMed ID: 21041957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid.
    Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M
    J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beyond rodent models of pain: non-human primate models for evaluating novel analgesic therapeutics and elaborating pain mechanisms.
    Hama AT; Toide K; Takamatsu H
    CNS Neurol Disord Drug Targets; 2013 Dec; 12(8):1257-70. PubMed ID: 24111837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization.
    Liu H; Zhang B; Liu X; Wang C; Ni J; Wang R
    Bioorg Med Chem; 2007 Feb; 15(4):1694-702. PubMed ID: 17188879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. When the DREAM is gone: from basic science to future prospectives in pain management and beyond.
    Cheng HY; Penninger JM
    Expert Opin Ther Targets; 2003 Apr; 7(2):249-63. PubMed ID: 12667101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What can chronic arthritis pain teach about developing new analgesic drugs?
    Witter J; Dionne RA
    Arthritis Res Ther; 2004; 6(6):279-81. PubMed ID: 15535840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Fragment-based screening: a promising avenue for drug design].
    Krimm I
    Med Sci (Paris); 2015 Feb; 31(2):197-202. PubMed ID: 25744267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-throughput structure-based pharmacophore modelling as a basis for successful parallel virtual screening.
    Steindl TM; Schuster D; Wolber G; Laggner C; Langer T
    J Comput Aided Mol Des; 2006 Dec; 20(12):703-15. PubMed ID: 17009092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted scoring functions for virtual screening.
    Seifert MH
    Drug Discov Today; 2009 Jun; 14(11-12):562-9. PubMed ID: 19508918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergies of virtual screening approaches.
    Muegge I
    Mini Rev Med Chem; 2008 Aug; 8(9):927-33. PubMed ID: 18691150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Virtual screening strategies in drug discovery.
    McInnes C
    Curr Opin Chem Biol; 2007 Oct; 11(5):494-502. PubMed ID: 17936059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computer-Assisted Drug Virtual Screening Based on the Natural Product Databases.
    Yang B; Mao J; Gao B; Lu X
    Curr Pharm Biotechnol; 2019; 20(4):293-301. PubMed ID: 30919773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.